Table 3.

Comparison of Serum Antibody Titers after Intranasal (IN) or Subcutaneous (SC) Route of Vaccination^a

	after prime	after boost
Anti-OVA Serum IgG Titer (Log10)
PBS control-IN	0.49 ± 0.33	0.47 ± 0.31
CTB (10 µg OVA)-IN	1.70 ± 0.49	4.11 ± 0.31####
MPs (10 µg OVA)-IN	0.90 ± 0.46	2.55 ± 0.47##, †
MPs (10 µg OVA)-SC	5.85 ± 0.21****	7.32 ± 0.14****
Anti-OVA Serum IgG1 Titer (Log10)
PBS control-IN	N.B.	N.B.
CTB (10 µg OVA)-IN	0.77 ± 0.51	4.41 ± 0.39####
MPs (10 µg OVA)-IN	0.934 ± 0.34	2.48 ± 0.58###,††
MPs (10 µg OVA)-SC	4.84 ± 1.22****	7.74 ± 0.11####,††††,‡‡‡
Anti-OVA Serum IgG2C Titer (Log10)
PBS control-IN	N.B.	0.63 ± 0.43
CTB (10 µg OVA)-IN	N.B.	0.63 ± 0.43
MPs (10 µg OVA)-IN	N.B.	0.50 ± 0.33
MPs (10 µg OVA)-SC	N.B.	4.80 ± 0.22****

^aThe data for MPs (10 µg OVA)-SC is from Bailey et al.¹⁴ Data represent mean ± SEM (n = 10 for PBS-IN, CTB-IN, and MPs-IN; and n = 5 for MPs-SC).

^****p < 0.0001 against all other groups.

^##p ≤ 0.01;

^###p ≤ 0.001;

^####p ≤ 0.0001 against PBS control-IN.

^†p ≤ 0.05;

^††p ≤ 0.01;

^††††p ≤ 0.0001 against CTB-IN.

^‡‡‡p ≤ 0.001 against MPs-IN. N.B. = no binding detected.